Antiviral composition comprising a sulfated polysaccharide
Inventors
Grassauer, Andreas • Prieschl-Grassauer, Eva
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10342820-B2
Publication Date
2019-07-09
Expiration Date
Abstract
The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.
Core Innovation
The invention addresses upper respiratory tract infections caused by a virus selected from paramyxovirus, human influenza A virus, and adenovirus of subtype B by using a carrageenan component as the sole antiviral active ingredient in an antiviral effective amount. The carrageenan component comprises iota-carrageenan, or kappa-carrageenan, or a combination of iota- and kappa-carrageenan, or salts thereof, in an amount of 80% by weight or more relative to the total dry weight of all carrageenans or salts thereof present in the composition.
The pharmaceutical composition is administered topically on skin or mucosa and does not contain a surfactant. The invention presents antiviral effect through carrageenan, including intervention with viral actions and reduction of virus levels in a eukaryotic or mammalian host system.
The antiviral effect is described as either specifically interfering with viral actions selected from virus penetration of eukaryotic cells, virus replication in eukaryotic cells, virus assembly, and virus release from infected eukaryotic cells, or unspecifically inhibiting a virus titer increase or unspecifically reducing a virus titer level. The disclosure further describes carrageenan and fucoidan as antiviral active ingredients for prophylaxis/treatment of respiratory viral infections.
Claims Coverage
The document contains two independent claims. Both cover treating upper respiratory tract infections by topical administration of a carrageenan-only pharmaceutical composition as the sole antiviral active ingredient, with additional constraints on carrageenan composition and amount, exclusion of surfactant, topical route, and the antiviral mode of action.
Topical carrageenan-only antiviral treatment for upper respiratory tract infections
A method of treating a subject having an upper respiratory tract infection caused by a virus selected from paramyxovirus, human influenza A virus, and adenovirus of subtype B by administering to the subject a pharmaceutical composition comprising a carrageenan component as the sole antiviral active ingredient in an antiviral effective amount, wherein the carrageenan component is the sole antiviral active ingredient administered, and the pharmaceutical composition is administered topically on skin or mucosa.
Carrageenan dominance without surfactant in the topical composition
The carrageenan component comprises iota-carrageenan, or kappa-carrageenan, or a combination of iota- and kappa-carrageenan, or salts thereof in an amount of 80% by weight or more relative to the total dry weight of all carrageenans or salts thereof present in the composition, wherein the pharmaceutical composition does not contain a surfactant.
Antiviral effectiveness via specific viral action interference or unspecific titer level reduction
The active antiviral ingredient is effective in treating the upper respiratory tract infection by either specifically interfering with at least one viral action selected from virus penetration of eukaryotic cells, virus replication in eukaryotic cells, virus assembly, and virus release from infected eukaryotic cells, or unspecifically inhibiting a virus titer increase or unspecifically reducing a virus titer level in a eukaryotic or mammalian host system.
Across the independent claims, the inventive coverage centers on topical treatment of upper respiratory tract infections using a pharmaceutical composition where carrageenan (iota and/or kappa, or salts) is the sole antiviral active ingredient at high dominance (80% by weight or more), with no surfactant, and with antiviral effectiveness defined via either specific interference with defined viral actions or unspecific inhibition of virus titer increase/reduction.
Stated Advantages
The invention presents antiviral effect through carrageenan, including intervention with viral actions and reduction of virus levels in a eukaryotic or mammalian host system.
The disclosure further supports a mechanistic concept that carrageenan can act at the respiratory-tract entry to prevent viral attachment or action, including persistence after carrageenan removal for certain viruses.
Documented Applications
Treatment and prophylaxis of respiratory viral infections.
Topical administration on skin or mucosa for upper respiratory tract infections.
Interested in licensing this patent?